Evidence-based Screening Strategies for Celiac Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Celiac disease antibody screening.
- Who it may be relevant to
- Registry conditions: Celiac Disease. Basic parameters: 6 months — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Improving Case-finding Strategies for Celiac Disease in Family Members: a Follow-up Study
Overview
Main aim: To find evidence-based screening strategies for celiac disease in high risk groups and to find new biomarkers or biomarker combinations for celiac disease diagnostics and follow-up.
Detailed description
The current project will result in the identification of genetic, environmental or downstream biomedical markers that predict the development of celiac disease at the individual level. Moreover, the markers can be exploited in prediction of specific disease risks, manifestations, comorbidities and complications.
Interventions
- Diagnostic test Celiac disease antibody screening
Observational parameters
Primary outcome measures
- Forthcoming celiac disease diagnosed by current diagnostic criteria [Time frame: With in 10 years]
Eligibility criteria
Inclusion criteria
- Cohort 1: Family member of celiac disease patient
- Cohort 2: Previously diagnosed celiac disease
Exclusion criteria
- Cohort 1: No previous celiac disease
- Cohort 2: Celiac disease diagnosis not confirmed
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Finland · 1 center
- Tampere University Hospital / Tampere University — Tampere
Publications
- Paavola S, Kurppa K, Huhtala H, Saavalainen P, Lindfors K, Kaukinen K. Coeliac disease re-screening among once seronegative at-risk relatives: A long-term follow-up study. United European Gastroenterol J. 2022 Jul;10(6):585-593. doi: 10.1002/ueg2.12255. Epub 2022 May 25. PMID 35611878
- Paavola S, Lindfors K, Kivela L, Cerqueira J, Huhtala H, Saavalainen P, Tauschi R, Kaukinen K, Kurppa K. Presence of high-risk HLA genotype is the most important individual risk factor for coeliac disease among at-risk relatives. Aliment Pharmacol Ther. 2021 Sep;54(6):805-813. doi: 10.1111/apt.16534. Epub 2021 Jul 18. PMID 34278595
Identifiers
NCT: NCT03136731 · Celiac2017